Cannabis Report
Lithium
Home > Boards > US Listed > Medical - Drugs >

AVEO Pharmaceuticals, Inc. (AVEO)

AVEO RSS Feed
Add AVEO Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Apophis
Search This Board: 
Last Post: 8/18/2018 10:18:09 PM - Followers: 120 - Board type: Free - Posts Today: 0

AVEO ONCOLOGY, Inc. (AVEO) 

Company website: 
http://www.aveooncology.com/

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

   





Product pipeline candidates include Tivozanib, Ficlatuzumab, AV-203, AV-353 and AV-380.
 

AV-380 (GDF-15 Program)

In August 2015, AVEO announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody.

GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro- inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia.
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It affects some five million individuals in the United States.

Tivozanib

Tivozanib, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

AVEO remains encouraged by the clinical outcomes from its Phase 2 and Phase 3 studies in renal cell carcinoma and the efficacy and tolerability profile that tivozanib may offer to patients suffering from this challenging disease. In addition, promising biomarker results were observed in a Phase 2 study of tivozanib in colorectal cancer.

In August of 2014, AVEO regained all rights to tivozanib. In November 2014, AVEO entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye. In August 2015, AVEO entered into an exclusive license agreement with Pharmstandard OJSC for the development, manufacturing and commercialization of tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions. The Company is actively pursuing partnerships in Europe to advance the development and commercialization of tivozanib in solid tumors.

AVEO is interested in collaborating with potential partners who share our vision for cancer drug development and positively impacting patients’ lives. Please contact AVEO aveobd@aveooncology.com to discuss partnership opportunities with AVEO’s development pipeline.

European Medicines Agency (EMA), has approved on 8/28/17  FOTIVDA™ (tivozanib) for approval as a treatment (Solid Dose) for patients with advanced renal cell carcinoma (RCC)
 

Ficlatuzumab

Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) inhibitory antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities.

AVEO and Biodesix, Inc. have a worldwide agreement to develop and commercialize ficlatuzumab, with VeriStrat®, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO and Biodesix are conducting a proof-of-concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using BDX001, a serum protein test similar to the VeriStrat test.

An exploratory analysis from AVEO’s Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints
 

AV-203

AVEO scientists have demonstrated through the use of our Human Response Platform™ the importance of ErbB3 in promoting tumor growth. An increasing body of evidence also implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers.

AVEO has successfully completed a Phase 1 safety study showing no dose limiting toxicities at maximum dose of 20mg/kg and CLIA (Clinical Laboratory Improvements Amendment) validation has been completed for a biomarker for potential patient selection.

AV-353

AV-353 is the Company’s potent, selective, high affinity inhibitory antibody specific to Notch 3. The Notch 3 signaling pathway is important in cell-to-cell communication involving gene regulation mechanisms that control multiple cell differentiation processes during the entire life cycle. Scientific literature has implicated the Notch 3 receptor pathway in multiple diseases, including cancer, cardiovascular diseases and neurodegenerative conditions. Publications, including Nature Medicine (2009), have implicated the Notch 3 pathway in Pulmonary Arterial Hypertension (PAH). PAH is a rare and life-threatening disorder that affects approximately 250,000 people worldwide and is caused by enlargement of the arterial walls in small arteries between the heart and the lungs, resulting in restricted blood flow.

Current treatments in PAH focus only on controlling symptoms by avoiding vasoconstriction and increasing vasodilation of vessels and do not reverse the underlying cause of the disease. In contrast, with the results of a recently concluded preclinical animal studies supported by AVEO, AV-353 has generated a growing body of preclinical data that supports AV-353’s ability to potentially reverse the disease phenotype, which would represent a potential disease-modifying approach to treatment. AVEO is currently seeking a partner to develop and commercialize AV-353 worldwide in PAH.

For additional information, or to inquire about potential partnering opportunities, please contact Nikhil Mutyal (nmutyal@aveooncology.com).

 
www.aveopharma.com
Shares Outstanding   110,363,000
Insider Ownership 17%
Institutional + Mutual Fund Ownership  58%
20 Full Time Employees
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-irhome
 
  
One Broadway 14th Floor
Cambridge, MA 02142

Investor Relations
Phone: 617-588-1960
E-mail: ir@aveooncology.com

 
Cannabis Report
Lithium
AVEO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVEO News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 08/17/2018 05:26:45 PM
AVEO News: Current Report Filing (8-k) 08/17/2018 05:24:19 PM
AVEO News: AVEO Announces Pricing of $5.7 Million Public Offering of Common Stock 08/17/2018 09:10:00 AM
AVEO News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 08/17/2018 06:09:11 AM
AVEO News: AVEO Announces Proposed Offering of Common Stock 08/16/2018 06:34:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#3087  Sticky Note AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the Maple tree 08/28/17 06:46:30 AM
#1839  Sticky Note $AVEO recent news/filings mick 11/17/15 10:42:39 AM
#3778   Big new coming soon , big run coming. Apophis 08/18/18 10:18:09 PM
#3777   $1! harry crumb 08/18/18 01:16:33 PM
#3776   $1.80-$1.50 coming imo ?? Rogerthat1 08/17/18 07:55:10 AM
#3775   Told everyone big selloff coming. Dilution dilution an harry crumb 08/16/18 09:42:53 PM
#3774   Love the selling on the news? Apophis 08/14/18 01:47:42 PM
#3773   That happens often lol tonyjh 08/14/18 01:14:32 PM
#3772   Hmmmm. It looks like you're wrong. Biotech Pharmer 08/14/18 09:24:47 AM
#3771   Huge selloff coming! $$$ harry crumb 08/08/18 09:42:26 PM
#3770   Losing your shirt? JUST 10-11-12 08/08/18 02:49:31 PM
#3769   $1.90 is huge support here. That is the Biotech Pharmer 07/28/18 07:59:29 AM
#3768   * * $AVEO Video Chart 07-23-18 * * ClayTrader 07/23/18 05:15:32 PM
#3767   Aveo Pharmaceuticals (AVEO) mick 07/23/18 04:43:38 PM
#3766   * * $AVEO Video Chart 07-19-18 * * ClayTrader 07/19/18 05:21:49 PM
#3765   no way this is going lower than $1.70 MakinBank 07/19/18 10:32:15 AM
#3764   I’m sorry bud I know nothing about the Rogerthat1 07/18/18 11:05:16 PM
#3763   damn, this is way oversold. Didn't think there MakinBank 07/18/18 10:40:26 PM
#3762   Ummm what did I say. https://investorshub.advfn.com/boards/m_read_msg.aspx?messa Rogerthat1 07/18/18 07:24:41 PM
#3761   * * $AVEO Video Chart 07-18-18 * * ClayTrader 07/18/18 05:26:03 PM
#3760   AVEO in here at 2.00 bullish jet1968 07/18/18 01:07:24 PM
#3759   No opinion as I have trouble understanding this stockguard 07/18/18 12:10:53 PM
#3758   So very profound lmao tonyjh 07/18/18 12:06:57 PM
#3757   Heres the scoop shorts, break 2$, gonna get harry crumb 07/18/18 10:56:05 AM
#3756   * * $AVEO Video Chart 07-17-18 * * ClayTrader 07/17/18 05:05:34 PM
#3755   Broker got me 30k more! Wweeeee gonna make harry crumb 07/17/18 03:53:38 PM
#3754   Cant wait to see how many insiders an harry crumb 07/17/18 03:42:21 PM
#3753   when do you think the 255 PFS events MakinBank 07/17/18 03:10:48 PM
#3752   MakinBank I posted this on the thread last night stockguard 07/17/18 03:03:56 PM
#3751   Gonna short this to .50!! $$$$ harry crumb 07/17/18 02:58:05 PM
#3750   This company is finished! Major shorting taking place, harry crumb 07/17/18 02:53:00 PM
#3749   where is the news that they pushed the MakinBank 07/16/18 10:44:11 PM
#3748   Umm going under $2 tomorrow. Not $20. Not Rogerthat1 07/16/18 08:55:55 PM
#3747   Too much risk for this play, out....... stockguard 07/16/18 04:58:49 PM
#3746   * * $AVEO Video Chart 07-16-18 * * ClayTrader 07/16/18 04:56:47 PM
#3745   $3 options expiring next Friday Biotech Pharmer 07/13/18 03:30:38 PM
#3744   A struggle to get past $3.00 this week Apophis 07/13/18 02:17:26 PM
#3743   AVEO: Better Chart here. Nice action. Eagle1 07/12/18 08:51:49 PM
#3742   AVEO: Solid Gains here. Golden cross on the Eagle1 07/12/18 08:35:42 PM
#3741   There are preferred stock and 119 M common Apophis 07/11/18 04:23:09 PM
#3740   15 bucks Apophis 07/11/18 11:36:54 AM
#3739   How much will be the shares for 2 youssef 07/11/18 10:44:19 AM
#3738   Love to see a 2 billion dollar buyout soon. Apophis 07/11/18 06:50:46 AM
#3737   * * $AVEO Video Chart 07-10-18 * * ClayTrader 07/10/18 04:43:55 PM
#3736   * * $AVEO Video Chart 07-09-18 * * ClayTrader 07/09/18 05:20:06 PM
#3735   https://www.scottishmedicines.org.uk/about-us/latest-updates/july-2018-decisions Apophis 07/09/18 03:36:09 PM
#3734   I couldn’t open the news I just red youssef 07/09/18 03:33:21 PM
#3733   No solid news? Apophis 07/09/18 03:31:07 PM
#3732   I got an email from seeking alpha about youssef 07/09/18 03:22:18 PM
#3731   rumors about Scotland approval , I did not Apophis 07/09/18 03:19:57 PM
#3730   Seeking alpha had some news but I couldn’t youssef 07/09/18 02:13:05 PM
#3729   I m buying weekly youssef 07/08/18 10:07:02 PM
PostSubject